ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005644

amebiasis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. amebiasis. Diseases, record MONDO_0005644. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005644

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
amebiasis
Open Targets
Open Targets ID
MONDO_0005644
Open Targets
Other names
amoebiasis, entamoebiasis
Open Targets
Disease Ontology
DOID:9181
Disease Ontology
MeSH
D000562
MeSH
NCI Thesaurus
C84551
NCI Thesaurus
Highest stage of its drugs
Approval, for 31 of its 32 drugs, from ATC, DailyMed and TTD
Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
METRONIDAZOLECHEMBL137Small moleculeApprovalATC and TTD300Drugs and targets
CLIOQUINOLCHEMBL497Small moleculeApprovalATC200Drugs and targets
EMETINECHEMBL50588Small moleculeApprovalATC200Drugs and targets
GLYCOBIARSOLCHEMBL1788392Small moleculeApprovalATC200Drugs and targets
ORNIDAZOLECHEMBL1449676Small moleculeApprovalATC and TTD200Drugs and targets
SECNIDAZOLECHEMBL498847Small moleculeApprovalATC and TTD200Drugs and targets
TINIDAZOLECHEMBL1220Small moleculeApprovalATC and DailyMed200Drugs and targets
ARSTHINOLCHEMBL1788384Small moleculeApprovalATC100Drugs and targets
ATOVAQUONECHEMBL1450Small moleculeApprovalATC100Drugs and targets
AZANIDAZOLECHEMBL134920Small moleculeApprovalATC100Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials1

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked by
NCT02736968Auranofin for Giardia ProtozoaPhase 2932023-01-26Amoebic Dysentery, GiardiasisAURANOFINIts record names the disease

Source ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Symptomatic Giardia- Auranofin vs Symptomatic Giardia- Placebo: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose Stools/24 Hours)
28 of 2928 of 2958NCT02736968Trial comparisons
Asymptomatic Giardia- Auranofin vs Asymptomatic Giardia- Placebo: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia at Enrollment With Parasitological Response (no Detection of Cysts or Trophozoites on Microscopic Exam or Negative Antigen Test)
6 of 146 of 1428NCT02736968Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005644

GET https://conductscience.org/api/diseases/v1/MONDO_0005644/drugs?page=2

API referenceFor AI assistants